RASONQUE
REVOLUTION MEDICINES · DARAXONRASIB
Open FDA's page for this record- Application number
- NDA220910
- Sponsor name
- REVOLUTION MEDICINES
- Submissions
- Submission type
- ORIG
- Submission number
- 1
- Submission status
- AP
- Submission status date
- 20260826
- Review priority
- PRIORITY
- Submission class code
- TYPE 1
- Submission class code description
- Type 1 - New Molecular Entity
- Submission property type
- Code
- Orphan
- Application docs
- ID
- 87060
- Url
- https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220910Orig1s000ltr.pdf
- Date
- 20260828
- Type
- Letter
- ID
- 87078
- Url
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220910Orig1s000lbl.pdf
- Date
- 20260901
- Type
- Label
- ID
- 87090
- Url
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220910Orig1s000lbl.pdf#page=20
- Date
- 20260901
- Type
- Medication Guide
- Products
- Product number
- 001
- Reference drug
- Yes
- Brand name
- RASONQUE
- Reference standard
- No
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Prescription
- Active ingredients
- Name
- DARAXONRASIB
- Strength
- 100MG
- Product number
- 002
- Reference drug
- Yes
- Brand name
- RASONQUE
- Reference standard
- Yes
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Prescription
- Active ingredients
- Name
- DARAXONRASIB
- Strength
- 150MG
- Harmonized identifiers (openFDA)
- Application number
- NDA220910
- Brand name
- RASONQUE
- Generic name
- DARAXONRASIB
- Manufacturer name
- Revolution Medicines, Inc.
- Product NDC
- 85219-101, 85219-104
- Product type
- HUMAN PRESCRIPTION DRUG
- Route
- ORAL
- Substance name
- DARAXONRASIB
- RxCUI
- 2750160, 2750166, 2750168, 2750170
- SPL ID
- 107d4cd9-2e5e-419d-9449-7ef84f5fbcc9
- SPL set ID
- 13a65923-d072-4dac-8620-8eabbf8c3641
- Package NDC
- 85219-101-01, 85219-104-01
- UNII
- B6T47Y2UAP
